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Recombinant subunit vaccines are some of the safest and most effective vaccines
available, but their high cost and the requirement of advanced medical infrastructure
for administration make them impractical for many developing world diseases. Plant-
based vaccines have shifted that paradigm by paving the way for recombinant vaccine
production at agricultural scale using an edible host. However, enthusiasm for “molecular
pharming” in food crops has waned in the last decade due to difﬁculty in developing
transgenic crop plants and concerns of contaminating the food supply. Microalgae could
be poised to become the next candidate in recombinant subunit vaccine production,
as they present several advantages over terrestrial crop plant-based platforms including
scalable and contained growth, rapid transformation, easily obtained stable cell lines,
and consistent transgene expression levels. Algae have been shown to accumulate and
properly fold several vaccine antigens, and efforts are underway to create recombinant
algal fusion proteins that can enhance antigenicity for effective orally delivered vaccines.
These approaches have the potential to revolutionize the way subunit vaccines are made
and delivered – from costly parenteral administration of puriﬁed protein, to an inexpensive
oral algae tablet with effective mucosal and systemic immune reactivity.
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INTRODUCTION
Infectious diseases directly account for nearly 25% of deaths
worldwide, and are a predominant cause of morbidity and mor-
tality in the developing world (Fauci et al., 2005). Even for diseases
for which vaccines exist, limited access – due to ﬁnancial as well as
infrastructural or medical personnel limitations – is a major con-
tributor to this high infectious disease burden. Many developing
world diseases do not yet have vaccines, in part because traditional
vaccine production costs present a signiﬁcant investment hurdle,
considering the ﬁnancial capacity of the intended consumers. Both
cost and ease of administration are challenges that must be tackled
to address this undue burden on global health and productivity.
Oral vaccination has many distinct advantages over parenteral
administration, but has proven difﬁcult to achieve thus far,
reﬂected by the scarcity of licensed oral vaccines. Perhaps the most
signiﬁcant beneﬁt of oral vaccination is the ability to elicit both
mucosal and systemic immunity. As most human pathogens enter
via mucosal surfaces – either nasally, orally, or by sexual trans-
mission – mucosal immunity can serve as a ﬁrst line of defense
to prevent infection before it reaches the bloodstream (Mason
and Herbst-Kralovetz, 2012). Oral vaccines also obviate the need
for trained medical personnel to administer them and reduce the
risks of infection associated with needles. They also have higher
compliance from patients, owing to the lack of fear and resistance
associated with injections. Both of these latter aspects are impor-
tant considerations for successful vaccination campaign coverage
in remote or resource-limited settings.
Plant-produced vaccines have two critical advantages: much
lower cost than traditional recombinant vaccine platforms,
and improved safety because of insusceptibility to mammalian
pathogen contamination. The batch costs of plant-produced
vaccines may be as much as a thousand times less than traditional
animal cell culture or even bacterial or yeast cell culture, though
it has been noted that this will not translate directly to per-dose
cost because downstream sales, packaging, and distribution costs
are similar regardless of production method (Rybicki, 2009). The
current status of plant-produced vaccines in pre-clinical and early
phase human clinical trials has been extensively reviewed (Lossl
and Waheed, 2011; Mason and Herbst-Kralovetz, 2012; Rosales-
Mendoza et al., 2012a,b; Guan et al., 2013; Jacob et al., 2013);
despite positive preliminary data, none have made it through to
licensing. The only licensed plant-produced vaccine is a veteri-
nary injectable vaccine against Newcastle disease virus in poultry,
made from puriﬁed antigen expressed in cultured tobacco cells.
DowAgroSciences received Food and DrugAdministration (FDA)
approval for the vaccine in 2006, but only as a demonstration
that plant-produced vaccines can meet the stringent regulatory
requirements for approval; it is not currently for sale (Rybicki,
2009).
Plant cells are of particular interest for oral vaccines because
their rigid cell walls provide exceptional antigen protection
through the stomach into the intestines, where they can access
the gut-associated lymphoid tissue (Kwon et al., 2013). Expression
within chloroplasts or other storage organelles may also provide
additional protection (Khan et al., 2012). While vaccine antigens
have been transformed into many edible species including lettuce,
tomato, potato, and tobacco, expression in stable transformed crop
plants has suffered from low yields, typically less than 1% of total
soluble protein (TSP; Lossl and Waheed, 2011). Yields have been
increased by transient expression using recombinant viral vectors
orAgrobacterium infection, but this expression is typically unstable
(Rybicki, 2009). Even using these strategies, the most consistently
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high-yielding host species is tobacco, which is inedible and there-
fore would require puriﬁcation prior to vaccine administration
(Lossl and Waheed, 2011).
ALGAE AS A RECOMBINANT PROTEIN PRODUCTION PLATFORM
Green microalgae have proven to be highly useful protein pro-
duction platforms for a variety of industrial and therapeutic
applications, particularly for complex or heavily disulﬁde-bonded
proteins. The chloroplast provides a unique enclosed com-
partment that facilitates folding (Chebolu and Daniell, 2009),
and transgene products have been shown to accumulate to
high levels in the algal chloroplast – as high as 10% of TSP
(Manuell et al., 2007; Surzycki et al., 2009). Unlike prokaryotes,
chloroplasts of algae contain much of the same sophisticated
cellular folding machinery as other eukaryotic organisms like
yeast. While the algal nuclear genome can also be transformed,
to date most transgene expression has been from the chloro-
plast genome due to reduced gene silencing and higher protein
accumulation.
The green algamodel organismChlamydomonas reinhardtii has
been used to produce a number of human and animal therapeu-
tically relevant proteins, including full-length human antibodies
(Tran et al., 2009), signaling molecules such as vascular endothe-
lial growth factor (Rasala et al., 2010), and structural proteins
like ﬁbronectin (Rasala et al., 2010). Though expression levels
are highly variable by gene, improvements in codon optimization
(Franklin et al., 2002; Surzycki et al., 2009) and characterization
of ideal gene regulatory elements (Rasala et al., 2011; Specht and
Mayﬁeld, 2013) continue to increase levels of transgene expres-
sion. C. reinhardtii’s success and future potential as a therapeutic
protein production platform has been recently reviewed (Rasala
and Mayﬁeld, 2011).
ADVANTAGES OF AN ALGAL VACCINE PRODUCTION HOST
Unicellular green algae possess all the positive attributes of plant
systems, plus several unique advantages over terrestrial plants
as vaccine production hosts. Algal biomass accumulation is
extremely rapid, and the entirety of the biomass can be utilized
for vaccine production, unlike plants that expend energy produc-
ing supporting tissues that do not contain the vaccine antigen or
cannot be harvested easily. Algae are also not restricted by growing
season or local soil fertility, and concerns of cross-contamination
of nearby food crops are non-existent. Enclosed bioreactors can be
used for higher biomass yields and to reduce concerns of environ-
mental escape (Franconi et al., 2010), and media can be recycled to
minimizewater andnutrient loss. The 2002discoveryof transgenic
viral capsid protein-expressing maize in food harvests of nearby
corn and soybean crops effectively halted efforts to produce vac-
cines in edible crop plants, making a food crop-based oral vaccine
highly unlikely (Rybicki, 2009). Green algae such as C. reinhardtii
are generally recognized as safe (GRAS) by the FDA, resurrect-
ing hope that unprocessed edible vaccines can be produced in a
photosynthetic organism.
Crop plants can contain hundreds of chloroplasts per cell, and
each chloroplast harbors dozens of copies of its plastid genome.
In contrast, C. reinhardtii contains a single chloroplast that occu-
pies about half of the volume of the cell (Franklin and Mayﬁeld,
2005), making stable homoplasmic transformed lines much eas-
ier to obtain (a few weeks versus several months) and allowing
for increased yields of plastid-expressed vaccine antigens, which
account for nearly all antigens expressed to date in algae. This
genomic stability, combined with the ability to tightly regulate
growth conditions inside contained bioreactors, allows for more
consistent expression levels than terrestrial plants, which can vary
by several-fold.
Finally, algae can be easily preserved by lyophilization, and
two studies of algal-produced vaccine antigens have veriﬁed that
dried algae stored at room temperature for 6 months (Gregory
et al., 2013) or even 20 months (Dreesen et al., 2010) exhibit
nearly equivalent antigen effectiveness as freshly harvested algae,
though storage at 37◦ did begin to cause a loss of activity over
time (Gregory et al., 2013). The algal cell wall appears sufﬁ-
cient to withstand harsh conditions within the stomach, as very
little antigen degradation was observed after whole cells were
incubated with pepsin at pH 1.7 (Dreesen et al., 2010). These
observations indicate that algae are an ideal host for vaccine
transport without cold-chain supply, and that the cells provide
adequate protection for antigens en route to the intestinal mucosal
lymph tissue, obviating the additional expense associated with
encapsulation.
ALGAL VACCINE PROGRESS
The ﬁrst reported algal-synthesized vaccine antigenwas a chimeric
molecule comprising the foot-and-mouth disease virus structural
proteinVP1 and the beta subunit of cholera toxin (CTB), a known
mucosal adjuvant (Sun et al., 2003). This antigen had been pre-
viously expressed in plants and had demonstrated oral immunity
in mice (Wigdorovitz et al., 1999), but advancement of trials was
hindered by low expression levels. In C. reinhardtii, 3–4% TSP was
reported, but higher yields may be possible because the strains
examined were not completely homoplasmic (Sun et al., 2003).
The next report of an algal-produced vaccine antigen showed
the ﬁrst in vivo data for efﬁcacy conferring immunity. The clas-
sical swine fever virus (CSFV) surface protein E2 was expressed
from the C. reinhardtii chloroplast genome, and total pro-
tein extracts were administered subcutaneously with Freud’s
adjuvant or orally by gavage with no adjuvant. Subcuta-
neous immunization reportedly induced a signiﬁcant immune
response, but no data for this result was shown. No sys-
temic or mucosal immune response was detected after the
oral immunization, and it was suggested that a mucosal adju-
vant may be necessary for oral administration to be effective
(He et al., 2007).
Wang et al. (2008) expressed the human glutamic acid decar-
boxylase, a known Type 1 diabetes autoimmune antigen, which
reacted with sera from non-obese diabetic mice. Surprisingly,
detectable expression was achieved using a non-codon-optimized
gene. A more thorough investigation of the factors affecting
vaccine antigen expression in algae found that indeed codon opti-
mization is critical for high yield. It has also been noted that
yield is highly variable among individual transformants despite
the fact that chloroplast transformation proceeds by homologous
recombination, eliminating positional effects within the genome
(Surzycki et al., 2009).
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Oral immunization was ﬁnally shown to be effective when the
antigen of interest was fused to the B subunit of CTB,which forms
a pentameric structure and binds the GM1 ganglioside for inter-
nalization into intestinal cells. After feeding freeze-dried algae
repeatedly to mice, fecal IgA and systemic IgG antibody titers
reached similarly high levels for both the intended Staphylococcus
aureus antigen and CTB. Signiﬁcantly, within a week of ﬁnishing
the 5-week oral vaccination, 80% of immunized mice survived a
lethal challenge with S. aureus that killed all control mice within
48 h (Dreesen et al., 2010).
Two studies earlier this year reported relatively low yields of
two additional algal-produced antigens, but they are still promis-
ing compared to previous literature using alternative systems. A
human papillomavirus E7 protein, while only accumulated to
0.12% TSP, expressed similar to or better than in other plant
systems and did not require fusion to a stabilizing protein to
achieve consistent expression. Furthermore, the algal chloroplast-
produced E7 was soluble, whereas the plant-produced E7 was
found predominantly in the insoluble fraction using multiple sol-
ubilization buffers. While the antibody titer elicited by afﬁnity
puriﬁed protein was much higher, a crude algal extract was shown
to be equally effective at preventing tumor development and pro-
motingmouse survival (Demurtas et al., 2013). A chimeric antigen
intended to prevent hypertension, consisting of a fusion between
angiotensin and a Hepatitis B antigen as a carrier, was the ﬁrst algal
vaccine to be expressed from the nuclear genome without chloro-
plast targeting. While it only accumulated to 0.05% TSP, it was
detectable by Western blot from algal TSP extracts (Soria-Guerra
et al., 2014).
Since 2010, several studies have shown that malarial
transmission-blocking vaccines can be produced in C. reinhardtii.
Transmission-blocking vaccines target surface proteins that appear
on the sexual and gamete stages of Plasmodium, the causative
pathogen of malaria. There is some evidence that these vac-
cines may provide partial protection to individuals, but the
main beneﬁt of vaccination with a transmission-blocking vac-
cine is derived from herd immunity preventing the spread of
the disease. Therefore, it is especially critical that transmission-
blocking vaccines can be delivered easily and at extremely low
cost, to reach threshold coverage of the huge populations living
in malaria-endemic regions. One difﬁculty of producing these
Plasmodium surface proteins is that they contain multiple EGF-
like domains that are heavily disulﬁde-bonded, rendering them
difﬁcult to fold and therefore difﬁcult to accumulate to high lev-
els without forming insoluble aggregates (Gregory et al., 2012).
Interestingly, Plasmodia appear to not glycosylate their proteins
(Gowda and Davidson, 1999), making algal chloroplasts suit-
able hosts as the chloroplast also does not contain glycosylation
machinery.
A total of six algae-produced malarial antigens or fragments
thereof – Pfs25,Pfs28,Pfs48/45,PfMSP1,PbMSP1, and PbAMA1 –
have been shown to fold properly and exhibit antibody recog-
nition akin to that of the native Plasmodium surface proteins
(Dauvillée et al., 2010; Gregory et al., 2012; Jones et al., 2013).
Algal chloroplast-produced Pfs25 was able to completely prevent
malaria transmission, indicated by a total absence of Plasmod-
ium oocysts in mosquito midguts after feeding on immunized
mouse sera. Furthermore, feeding lyophilized algae expressing
Pfs25 fused to CTB elicited a mucosal response to both antigens
(Gregory et al., 2013). However, systemic IgG response was only
observed for the CTB. This is in contrast with the S. aureus D2pro-
tein fused to CTB, where systemic immunity was elicited for both
domains (Dreesen et al., 2010), suggesting that either the furin
protease cleavable linker between the Pfs25 and CTB domains pre-
ventedPfs25 frombeing presented to the systemic immune system,
or perhaps that Pfs25 is inherently less immunogenic. In a differ-
ent strategy, truncated versions of the malarial proteinsAMA1 and
MSP1 were fused to the major protein constituent of the chloro-
plast starch granules, the granule-bound starch synthase (GBSS).
Though they were expressed from the nuclear genome, reasonable
accumulation was achieved because the proteins were targeted to
and sequestered within the chloroplast starch granules. Both oral
and injected vaccination using puriﬁed starch from these strains
reduced parasite load and prolonged mice survival after challenge
with Plasmodium berghei; in the case of an injected vaccine con-
sisting of both antigens, 30% of mice survived the otherwise-lethal
infection (Dauvillée et al., 2010).
All vaccines produced in algae to date are summarized in
Table 1, along with reported yields and signiﬁcant pre-clinical
ﬁndings. Most work thus far has been performed in the green
alga model organism C. reinhardtii, though one of the earli-
est reports of an algal-produced hepatitis B antigen was in the
marine alga Dunaliella salina (Geng et al., 2003) and hepatitis
B antigen has also been produced in the diatom Phaeodacty-
lum tricornutum (Hempel et al., 2011). In recent years the algal
genetic toolkit has been expanded to other algal species, includ-
ing other green algae, diatoms, and cyanobacteria (Ducat et al.,
2011; Georgianna and Mayﬁeld, 2012; Qin et al., 2012), with a
goal of broad host range compatibility. Already, over 20 species
of algae – including dinoﬂagellates, red algae, and diatoms – have
been transformed, and a suite of promoters and selectable mark-
ers have been characterized for many species (see Gong et al.,
2011, for a comprehensive review). While the ﬁrst generation
of algal vaccines has been predominantly pioneered in Chlamy-
domonas, these advances can readily be applied to alternative
algal species that may be more suitable for large-scale vaccine
production.
FUTURE POTENTIAL FOR ALGAL-BASED ORAL RECOMBINANT
VACCINES
From the research available to date, it is clear that algae canproduce
complex vaccine antigens, and that Chlamydomonas-produced
antigens can elicit immunogenic responses that are appropriate
for their intended roles as vaccines. It is also clear that identify-
ing alternative mucosal adjuvants to complement these antigens is
critical, whether for co-administration with algal-produced anti-
gens or for incorporation into chimeric fusion proteins. It has been
suggested that antigenic fusions with CTB, one of the preferred
adjuvants,may interfere with the CTB subunit’s ability to form the
pentameric structure essential for strongGM1ganglioside binding
(Sun et al., 2003). Many alternatives to CTB are under investiga-
tion for oral vaccination in other production platforms, including
CpG-containing oligodeoxynucleotides, saponins, and subunits
from heat-labile enterotoxin and ricin toxin (Pelosi et al., 2012).
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Table 1 | Summary of algal-produced vaccines and significant findings.
Antigen(s) Host/integration site Yield Significant findings Citation
Foot-and-mouth disease
virus (FMDV) structural
protein VP1 fused to cholera
toxin B subunit (CTB)
C. reinhardtii chloroplast
genome
3 to 4%TSP Protein accumulation was higher than reported
in previous plant studies and detectable by
Western and ELISA. Binding to GM1
ganglioside was weak but statistically
signiﬁcant. Strains were not completely
homoplasmic, so higher yields may be possible.
Sun et al. (2003)
Hepatitis B surface antigen
(HBsAg)
D. salina nuclear genome Up to 3ng/mg soluble
protein (0.0003%TSP)
Expression level was quantiﬁed by ELISA and
reported to be “high” but the results reﬂect
very low expression.
Geng et al. (2003)
Classical swine fever virus
(CSFV) structural protein E2
C. reinhardtii chloroplast
genome
1.5 to 2%TSP Subcutaneous immunization of algal extracts
induced systemic response, but oral
immunization did not result in either systemic
or mucosal response.
He et al. (2007)
Human glutamic acid
decarboxylase 65 (hGAD65)
C. reinhardtii chloroplast
genome
0.25 to 0.3%TSP Puriﬁed hGAD65 reacted with sera from
diabetic mice, showing antigenicity. Higher
yields may be obtained by codon-optimizing the
human gene, which does not mimic the
chloroplast AT content.
Wang et al. (2008)
White spot syndrome virus
VP28 protein
C. reinhardtii chloroplast
genome
Variable, ranging from
0.2 to 20.9% total
cellular protein (0.1 to
10.5%TSP)
The authors report high variability in expression
levels, despite same-site integration by
homologous recombination in the plastid
genome. Stronger resistance to antibiotic
selection might be useful for identifying
high-expressing strains.
Surzycki et al. (2009)
S. aureus D2
ﬁbronectin-binding domain
fused to cholera toxin B
subunit
C. reinhardtii chloroplast
genome
Up to 0.7%TSP Within whole cells, the antigen can withstand
low pH and pepsin treatment, and is stable at
room temperature for 20 months. Mice fed
with whole algae showed mucosal IgA and
systemic IgG responses to both CTB and D2,
and 80% survived lethal S. aureus challenge.
Dreesen et al. (2010)
P. falciparum MSP1, P.
berghei MSP1, and P.
berghei AMA1, C-terminal
domains only, fused to
granule-bound starch
synthase (GBSS)
C. reinhardtii nuclear
genome, targeted to the
chloroplast starch
granules
0.2 to 1.0 μg of
protein per mg of
puriﬁed starch
The P. falciparum gene expressed signiﬁcantly
better than either P. berghei gene. A single
dose was as effective as three doses in
reducing parasite load after P. berghei challenge
in vaccinated mice. Oral immunization with
puriﬁed starch protected equally well as
parenteral administration until day 40.
Dauvillée et al. (2010)
Hepatitis B surface antigen
(HBsAg) fused to GFP or ER
retention signal
P. tricornutum nuclear
genome
0.7%TSP By inhibitory ELISA, algal-produced HBsAg
binds antibodies slightly stronger than
commercially available HBsAg produced in
yeast.
Hempel et al. (2011)
(Continued)
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Table 1 | Continued
Antigen(s) Host/integration site Yield Significant findings Citation
P. falciparum surface
proteins Pfs25 and Pfs28
C. reinhardtii chloroplast
genome
Not quantiﬁed; visible
by Western and
Coomassie after
afﬁnity puriﬁcation
Conformation-speciﬁc antibodies and CD
spectroscopy conﬁrmed proper folding of
heavily disulﬁde-bonded antigens. Sera from
Pfs25-inoculated mice completely blocked
replication within mosquitoes, and therefore
malaria transmission.
Gregory et al. (2012)
P. falciparum surface protein
Pfs25 fused to cholera toxin
B subunit
C. reinhardtii chloroplast
genome
Up to 0.09%TSP Mice fed lyophilized algae showed mucosal
IgA response to both CTB and Pfs25, but only
systemic IgG response to CTB. A furin
protease site separated the two domains.
Gregory et al. (2013)
P. falciparum surface protein
Pfs48/45 C-terminal domain
C. reinhardtii chloroplast
genome
Not quantiﬁed; visible
by Western blot after
afﬁnity puriﬁcation
The antigenic C-terminal domain was
recognized by Western blot and ELISA with
conformation-speciﬁc antibodies. It appeared
to accumulate in the insoluble fraction.
Jones et al. (2013)
Human Papillomavirus type
16 E7 protein, attenuated
mutant (E7GGG)
C. reinhardtii chloroplast
genome
Up to 0.12%TSP.
His-tagged version
obtained only 0.02%
TSP.
In contrast to higher plant expression, C.
reinhardtii obtained much higher yields and
most of it was soluble. The crude algal extracts
elicited lower IgG response than puriﬁed
protein, but both preparations allowed 70%
survival after tumor challenge.
Demurtas et al. (2013)
Angiotensin II fused to
Hepatitis B virus capsid
antigen (HBcAg)
C. reinhardtii nuclear
genome
Up to 0.05%TSP The chimeric antigen was visible by Western
blot and quantitated by ELISA, but no in vivo or
immunological activity assays were performed.
Soria-Guerra et al. (2014)
Future work should empirically explore many combinations of
antigens, mucosal adjuvants, and even testing multiple linkers and
potential translocation domains. As has been noted previously,
expression, uptake, and antigenicity are all difﬁcult to predict
in the context of plant-produced oral vaccine antigens (Rybicki,
2009), so a high-throughput system like algae is extremely valu-
able for rapidly testingmany versions of potential chimeric vaccine
molecules. Furthermore, many antigens will require proper post-
translational modiﬁcations such as glycosylation to be recognized
properly; more work needs to be done to increase expression levels
from the nuclear genome, as glycosylation does not occur in the
chloroplast.
It has been suggested that the ﬁrst licensed plant-produced
human vaccines likely will not be the ﬁrst ones tested in humans,
many of which targeted pathogens like Hepatitis B for which
a relatively inexpensive vaccine already exists (Rybicki, 2009).
Stepping stones along the way to human vaccines may include
reagents for cheaper diagnostics and development of veterinary
vaccines. Several human studies with plant-made vaccines have
also indicated a role for oral boosting of an existing immune
response conferred by traditional injectable vaccines (Mason
and Herbst-Kralovetz, 2012). An algal-produced human vac-
cine production platform will likely come to fruition as an
alternative for very expensive vaccines like HPV, or for novel vac-
cines against diseases for which no alternative currently exists
(Martinez et al., 2012). The cost and logistical considerations
of storage, delivery, and administration in resource-limited set-
tings indicate that plant or algal production may be the only
feasible option for large-scale inexpensive vaccination, and thus
this avenue deserves increased attention from research funding
agencies and investment from the pharmaceutical industry as
well.
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